Advisors
Advisors provide strategic guidance and direction for Biological Dynamics' R&D and commercial operations. Advisors are industry leaders who have made significant contributions to the fields of genomics, nanotechnology, oncology, and clinical practice.
A board-certified oncologist, recipient of the NIH Physician-Scientist Award, and Director on public company Boards, Dr. Adler supports us with a blend of clinical, molecular, corporate and strategic perspectives. He served as CEO of San Diego Cancer Center (SDCC) for over 20 years until its purchase by UCSD. For nearly 20 years Dr. Adler was on the Board of WebMD. He served as Director on Boards of related companies, CareInsite and Medical Manager focusing, respectively, on delivering point-of-service patient information, and management software for physician offices.
Dr. Adler received his MD from the University of Pennsylvania. He received his B.A., summa cum laude, from Yale University.
Mark J. Adler, MD
In addition to being a renowned expert in nanotechnology and a UCSD professor of Bioengineering and Nanoengineering, Dr. Heller has been successful in fostering four companies and hundreds of students. As a mentor for Biological Dynamics' CEO, Raj Krishnan, he was instrumental in bringing ACE technology from its original concept to what it is today.
Dr. Heller continues to push the cutting edge of medical diagnostics in multiple areas, the most significant of these being serum markers for TBI. He has over 50 issued US patents related to microelectronic chips, microarrays and integrated devices for DNA hybridization, miniaturized sample-to-answer diagnostic devices, biosensors, genomics, proteomics, nanotechnology and nanofabrication, nano-based DNA optical storage, and fluorescent energy transfer in DNA.
Michael Heller, PhD
Dr. Ivor Royston served as Viracta’s founding President and CEO from 2015 until September 2022. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life science venture capital firm. From 1990 to 2000, Dr. Royston also held the position of Chief Executive Officer of the Sidney Kimmel Cancer Center. Prior to that, Dr. Royston was the Director of Clinical Immunology at University of California, San Diego Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed Rituxan, the first approved monoclonal antibody therapy for lymphoma, and which subsequently merged with Biogen to form Biogen Idec, now Biogen. Dr. Royston currently serves on the board of directors of Biocept, Inc. (NASDAQ:BIOC). Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University.
